Live Breaking News & Updates on Inhibrx inc

Stay updated with breaking news from Inhibrx inc . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported...

Chiesi-farmaceutici , Bristol-myers-squibb , Exchange-commission , Prnewswire-inhibrx-inc , Oxford-finance , Inhibrx-inc , Nasdaq , Security-agreement , Annual-report , Quarterly-reports , Current-reports , Private-securities-litigation-reform-act

Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported...

United-states , American , Bristol-myers-squibb , Exchange-commission , Prnewswire-inhibrx-inc , Oxford-finance , Inhibrx-inc , Nasdaq , American-thoracic-society , Security-agreement , Scientific-advisory-board , Annual-report

Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...

Massachusetts , United-states , Gainesville , Florida , Serbia , New-york , Stony-brook , United-kingdom , Cleveland , Ohio , Vancouver , British-columbia

Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...

San-francisco , California , United-states , American , Andrew-veale , Mark-brantly , Bristol-myers-squibb , Moscone-center , Inhibrx-inc , Nasdaq , American-thoracic-society , Late-breaking-mini

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...

United-states , American , Heather-kinkead , Katelynm-willis , Brendan-eckelman , Bristol-myers-squibb , Prnewswire-inhibrx-inc , American-association-for-cancer-research , Inhibrx-inc , Nasdaq , Cancer-research , Annual-meeting

Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported...

Bristol-myers-squibb , Exchange-commission , Prnewswire-inhibrx-inc , Oxford-finance , Inhibrx-inc , Nasdaq , Security-agreement , Annual-report , Quarterly-reports , Current-reports , Private-securities-litigation-reform-act , Media-contact

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...

Mark-lappe , Bristol-myers-squibb , Exchange-commission , Inhibrx-inc , Nasdaq , Annual-report , Quarterly-reports , Current-reports , Private-securities-litigation-reform-act , Media-contact , Inhibrx-inc- ,

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...

Mark-lappe , Bristol-myers-squibb , Exchange-commission , Inhibrx-inc , Nasdaq , Annual-report , Quarterly-reports , Current-reports , Private-securities-litigation-reform-act , Media-contact , Inhibrx-inc- ,

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...

United-states , Mark-lappe , Bristol-myers-squibb , Exchange-commission , European-union , Drug-administration , Office-of-orphan-products-development , Inhibrx-inc , Nasdaq , Inhibrx-chief-executive-officer-mark , Orphan-products-development , Fast-track

Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao,...

California , United-states , Finland , American , David-matly , Mark-lappe , David-kao , Eli-lilly , Bristol-myers-squibb , Brendan-eckelman , Kristiina-vuori , Jack-tsai